121 results about "Amino terminal" patented technology

The invention discloses a recombinant humanized XVII type collagen as well as an expression vector and a genetically engineered bacterium thereof. Four functional fragments with high activity are obtained through screening, one of the fragments is optimized and then combined according to a certain sequence to obtain recombinant humanized XVII type collagen JYC1703, or one of the fragments is optimized and then combined according to a certain sequence, and GPP sequences are fused at an amino terminal and a carboxyl terminal respectively to obtain recombinant humanized XVII type collagen JYC1701 and JYC1702, and the recombinant humanized XVII type collagen JYC1701 and JYC1702 are combined according to a certain sequence to obtain the recombinant humanized XVII type collagen JYC1701 and JYC1702. After codon optimization, amplifying and cloning into an expression vector, transforming into pichia pastoris competent cells after enzyme digestion linearization, and screening high-copy recombinants through G418 resistance gradient, so as to obtain pichia pastoris genetically engineered bacteria for expressing recombinant humanized XVII type collagen. The recombinant humanized XVII type collagen JYC1701, JYC1702 and JYC1703 disclosed by the invention show excellent functions of promoting cell adhesion, cell proliferation and cell migration, and are suitable for preparing products such as skin care products or medical instruments and the like.

Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase, wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing or FcRn-binding domain) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The invention relates to the technical field of electronic elements, in particular to a ternary compound for a memristor array and a preparation method of the ternary compound. The ternary complex comprises A, B and C, A is a guest molecule of a pyridine derivative with an amino terminal, B is a bridging molecule, and C is a host molecule with a cucurbituril structure. A, B and C are self-assembled in an aqueous solution through Van der Waals force and hydrophobic interaction among molecules to form a ternary complex; the host molecule C has a barrel-shaped cavity structure, and the guest molecule A and the bridging molecule B are included in the barrel-shaped cavity structure. The ternary complex forms a supramolecular chain junction at the end part of the graphene electrode, so that the graphene electrode with different gaps can be adapted, and the molecular connection success rate of the array is greatly improved. The preparation method of the ternary complex is simple, convenient, easy to operate and suitable for large-scale production.

The invention belongs to the technical field of gene engineering, and particularly relates to a strain for efficiently expressing beta-lactoglobulin as well as a construction method and application of the strain. By utilizing the beta-lactoglobulin expression vector disclosed by the invention, beta-lactoglobulin is guided to be secreted out of a host cell by an exogenous signal peptide, and efficient secretory expression of the beta-lactoglobulin in the host cell is realized by integrating a multi-copy expression cassette through a genome and co-expressing ATP enzyme Ssa4 participating in protein folding and coping with pressure; the amino terminal and the carboxyl terminal of the secreted and expressed beta-lactoglobulin do not contain redundant amino acids, and do not contain animal-derived components. Meanwhile, the invention provides a construction method and a fermentation culture method of the engineering strain, compared with a single-copy genetically engineered strain, the expression quantity of the genetically engineered strain in shake-flask fermentation is increased by 2.47 times, and the genetically engineered strain has a good industrial application prospect.

The invention relates to a second antibody for resisting mouse IgG and rabbit IgG as well as a preparation method and application of the second antibody. The second antibody of the anti-mouse IgG and the rabbit IgG sequentially comprises an anti-mouse IgG nano antibody, a biotin fixed-point binding peptide fragment and an anti-rabbit IgG nano antibody from an amino terminal to a carboxyl terminal. According to the design of the second antibody of the anti-mouse IgG and rabbit IgG with a brand-new structure and the preparation method, high-efficiency expression is realized, the second antibody of the anti-mouse IgG and rabbit IgG capable of realizing fixed-point biotinylation is obtained, the second antibody can be further subjected to various modification reformation based on a biotin-streptavidin bridge, the preparation method of the second antibody of the polymerase labeled anti-mouse IgG and rabbit IgG is further developed, and the application of the second antibody of the polymerase labeled anti-mouse IgG and rabbit IgG is expanded. According to the method, the polymerase-labeled mouse-rabbit universal secondary antibody with similar affinity to mouse IgG and rabbit IgG is obtained, the preparation period of the secondary antibody can be shortened, the preparation process of the secondary antibody is simplified, the stability between batches is improved, and meanwhile, the dependence on experimental animals is reduced.

The invention belongs to the technical field of biological detection, and particularly discloses a cardiovascular marker substance control product and a preparation method thereof, the cardiovascular marker substance control product comprises a serum matrix, an antigen, a preservative and a stabilizer; the antigens comprise a cardiac troponin I antigen, a creatine kinase isoenzyme antigen, a myoglobin antigen, an amino-terminal brain natriuretic peptide precursor antigen, a brain natriuretic peptide antigen, a D-dimer antigen, a heart-type fatty acid binding protein antigen, a myeloperoxidase antigen and a lipoprotein phospholipase A2 antigen; the stabilizer comprises at least one of D-trehalose, cane sugar, glycine, inositol and polyethylene glycol. The cardiovascular marker substance control substance disclosed by the invention can cover various cardiovascular disease markers including heart failure, pulmonary artery embolism, vasculitis, atherosclerosis, myocardial injury, myocardial infarction and the like. The quality control product disclosed by the invention can be used as a third-party quality control product for screening cardiovascular diseases and performing indoor and interventricular quality control on an auxiliary diagnosis and measurement system.

A system for delivering a payload nucleic acid into target cells of a subject and production of a payload (or payloads) encoded by the payload nucleic acid in the cells. The system includes a Bifidobacterium sp. bacterium comprising a plasmid and a transporter nucleic acid, the transporter nucleic acid configured for expression in the bacterium. The transporter nucleic acid encodes a transporter polypeptide comprising, in an amino-terminal to carboxy-terminal order, a bacterial secretion signal peptide, a DNA-binding domain to bind the plasmid, and a cell penetrating peptide. The transporter polypeptide complexes with the plasmid and transports the plasmid from the bacterium into the target cells. The plasmid encodes one or more payloads (protein and / or ribonucleic acid) for production in the target cells. The target cells may be colonic cells. When the payload(s) include an antigen, the system may be a DNA vaccine.

The invention belongs to the field of biological materials and biomedicine, and particularly relates to preparation and application of hydrogel. The hydrogel is composed of a polymer A and a polymer B, main chains of the polymer A and the polymer B are formed by amido bonds formed by polycondensation of lysine and glutamic acid, and the value of n is 8-100; alkynyl groups on main chains of the polymer A and the polymer B can be connected with functional molecules, and the functional molecules are selected from one or more of peptide fragments, fluorophores, antibacterial molecules, growth factors, functional oligosaccharides or polysaccharides; the amino terminal of the polymer A can be respectively connected with different kinds of monosaccharides or oligosaccharides; the amino terminal of the polymer B is connected with any one phenylboronic acid structure which comprises one or more of phenylboronic acid half ester and carbonyl phenylboronic acid half ester, and the hydrogel is good in biological safety and can be used for preparation of medical preparations and the like.

The present invention provides use of a C-JUN N-terminal kinase inhibitor, SU3327, in the preparation of a medicament for enhancing the efficacy of polymyxin against bacterial infection, and use of a composition of SU3327 and polymyxin in the preparation of a medicament for an enhanced efficacy against bacterial infection, wherein the polymyxin is preferably Polymyxin E. The invention not only shows an enhanced antibacterial activity of polymyxin by SU3327 in synergy through minimum inhibitory concentration tests in checkerboard assays and in vitro bacterial growth curves, but also confirms the ability of SU3327 to enhance polymyxin along with its effectiveness in vivo in the experiments with a model of mice infected with drug resistant bacteria at the animal level. The invention provides a new use of SU3327 in enhancing antibacterial activities of polymyxin antibiotics, resolving the technical problems such as clinical resistance to polymyxin, low clinical therapeutic index of polymyxin, etc.

The invention relates to the technical field of single-molecule devices, in particular to a single-molecule device for detecting small-molecule gas based on supramolecules and a preparation method of the single-molecule device. The monomolecular device comprises a functional molecule and a graphene electrode pair, wherein the functional molecule is connected between the graphene electrode pair through an amido bond. A cucurbituril hydrophobic cavity structure in the functional molecular structural formula can contain and capture target small molecular gas, gas molecules of different volumes are selectively included through multiple weak interaction, a dynamically-adjustable subject-object compound structure is formed, and then switching type sensing detection on the small molecular gas is achieved. The amino terminal of the end part of the main bridging unit in the functional molecule can be connected with the carboxyl terminal of the graphene point electrode in a covalent bond manner, and amide condensation molecular chain connection is formed at the two ends of the graphene point electrode, so that the stability of a monomolecular device is improved. The preparation method provided by the invention is simple in process, mild and controllable in reaction condition and beneficial to large-scale production.

The disclosure provides a polypeptide comprising (a) a sequence comprising alpha helices Hl, H2, H3 and H4, wherein, from an amino terminus to a carboxy terminus, a first loop (LI) connects Hl and H4, a second loop (L2) connects H4 and H2, a third loop (L3) connects H2 and H3, wherein the polypeptide binds to an IL-2 receptor beta-gamma (IL- 2Rβγ); and (b) a targeting moiety that binds to a sequence of a cluster of differentiation 8 (CD8) glycoprotein.

The invention discloses decapeptide with antioxidant activity, the amino acid sequence of the decapeptide is amino terminal-APKTLPWGPK-carboxyl terminal, and the decapeptide can be developed into an antioxidant.

The present application relates to a milk-derived phosphorylated peptide with the activity of improving intestinal iron absorption and its application in the preparation of iron supplements. The sequence of the milk-derived phosphorylated peptide is EESITRINKKIE, and the glutamic acid at the amino terminal of the sequence is connected with 1-3 phosphoserines. The milk-derived phosphorylated peptide can be combined with Fe 2+ Specifically bound, strong iron chelating ability, and can significantly improve the iron transport amount in the Caco-2 small intestinal epithelial cell model, thereby having good activity of improving intestinal iron absorption, and can be widely applied in the fields of drugs, health care products or food.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The present disclosure relates generally to transposase domains, in particular transposase domains comprising an amino terminal deletion, as well as transposase domains that form obligate heterodimers and transposase domains comprising a DNA targeting domain.

The invention relates to the field of biological medicines, in particular to an angiogenesis inhibition polypeptide specifically bound with an ITB3 target or pharmaceutically acceptable salt thereof, which is characterized in that the polypeptide is a) or b) or c) as follows: a) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 1-7, b) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 2-7, and c) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 3-7; b) a derivative polypeptide obtained by adding more than one amino acid residue to the amino terminal and / or carboxyl terminal of the polypeptide shown in any one amino acid sequence in SEQ ID NO: 1-7; and c) a derivative polypeptide obtained by adding or replacing more than one amino acid at any site of the polypeptide shown as any one amino acid sequence in SEQ ID NO: 1-7 except the amino terminal and the carboxyl terminal. The angiogenesis inhibiting polypeptide provided by the invention can specifically recognize and bind ITB3, can effectively inhibit angiogenesis, endothelial cell invasion and migration and target transfer in in-vivo and in-vitro experiments, is efficient and low in toxicity, and has potential effects of treating individual tumors, diabetic vascular proliferative diseases, rheumatoid arthritis and neovascular eye diseases.

Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.

The invention provides amino resin as well as a preparation method and application thereof in the preparation process of allyl glycidyl ether. The amino resin comprises a styrene skeleton and an amino terminal, chloromethylated polystyrene is swelled and then reacts with an amine compound, the amino resin is used for replacing alkali liquor to serve as an acid-binding agent for a ring-closure reaction of an allyl alcohol chlorohydrin ether intermediate in the preparation process of allyl glycidyl ether, chlorine salt is not generated, and the reaction time is shortened. The three-waste treatment cost is greatly reduced, and meanwhile, the prepared amino resin can be regenerated through heating and can be repeatedly used.

Activatable interleukin 12 (IL12) fusion proteins and constructs are disclosed herein that contain at least one of the following structures: N'-DD-L1-MM-L2-IL12-C', C'-DD-L1-MM-L2-IL12-N', N'-DD-L1-IL12-L2-MM-C', C'-DD-L1-IL12-L2-MM-N', wherein L1 is a first linker or is absent; L2 is a second linker; DD is a dimerization domain; MM is a masking moiety; IL12 comprises an IL12α (p35) domain and an IL12β (p40) domain; N' is an amino terminus of the activatable IL12 fusion protein; and C' is a carboxy terminus of the activatable IL12 fusion protein, wherein at least one of L1 and L2 comprises a cleavable moiety (CM); or a first IL12 subunit and a second IL12 subunit; at least one of a first linking region (LR1) and a second linking region (LR2); and a half-life extending moiety (EM), wherein at least one of the LR1 and the LR2 comprises a cleavable moiety (CM); or dimers thereof.

The application discloses a method for conformational signal peptide-mediated secretion and expression of heterologous proteins in Escherichia coli, and specifically comprises the following steps: simultaneously fusing at least two heterologous proteins to a conformational signal peptide (such as sfGFP) and constructing a heterologous recombinant protein expression vector, wherein the conformational signal peptide has a beta-barrel structure, and the fusion sites are at least two of the amino terminal end, the carboxyl terminal end and a plurality of loop rings of the conformational signal peptide; and then transforming the heterologous recombinant protein expression vector into Escherichia coli and culturing the obtained genetic engineering strain for expression. According to the method, the extracellular secretion and expression of the heterologous proteins in the Escherichia coli can be realized without the mediation of a classical signal peptide, the sfGFP as a fusion tag has no influence on the function of the target protein, and the corresponding target protein can be quickly expressed and purified; and the method expands the secretion and expression path of the protein, can realize the simultaneous expression of a plurality of heterologous proteins, and can effectively improve the expression amount of the target protein.

The BTK-C isoform is expressed in human breast and prostate cancer cells and it plays a crucial role in epithelial cancer cell survival. BTK-C has a 34 amino acid extension to the n-terminus that facilitate it being palmitoylated on two cysteine residues. This modification localizes BTK-C closer to the cell membrane where it plays a role in improving cancer cell survival, as compared to BTK-A. BTK-C is not found to be expressed in healthy adult cells, whereas BTK-A is necessary for immune cell production. Disclosed herein are alternative kinases besides BTK having similar attributes, which present therapeutic opportunities for the treatment of cancers, especially for solid tumors.

The invention relates to a biotinylation modified amino acid probe, a preparation method and application thereof, and a method and application for identifying amino acid binding protein. The amino acid probe is amino acid with biotin modification at an amino terminal or a carboxyl terminal; or, the amino acid probe is amino acid with an azide group at the carboxyl end, the amino acid probe reacts with alkynyl-containing biotin under the catalysis of copper ions through a click chemical reaction in a cell to generate biotin-modified amino acid, an azide-modified amino acid probe library is supplemented, and the amino acid probe is combined with immunoprecipitation and mass spectrometry technologies, so that the biotin-modified amino acid is obtained. Proteins capable of being directly combined with amino acids can be identified, an important tool is provided for follow-up research of amino acid sensing proteins, and the method has important application value in identification of amino acid binding proteins, research of amino acid sensing mechanisms and functions and determination of drug targets or screening of lead compounds.

Disclosed are virus-inspired compositions and preparation methods thereof, where the compositions comprise mutant papillomavirus L1 proteins that spontaneously form capsid backbones and that are conjugated to a peptide comprising an epitope to form immune redirector capsids (IRCs). The epitopes on the peptides are designed to be recognized by a subject's immune system based on the subject's preexisting immune memory developed from the subject's past exposure to the epitope through infection or vaccination. The mutant papillomavirus L1 proteins possess three mutations including an amino-terminal truncation, a carboxy-terminal truncation, and a truncation at helix four. These mutations in the L1 protein yield capsomeres that are form non-canonical T=1 geometry capsid backbones. Disclosed are uses and methods of using the compositions in treating and / or preventing cancers in subjects in need thereof.

The invention discloses a multivalent expression sheep listeria vaccine for cervical cancer and a preparation method thereof, and the method comprises the following steps: on the basis of replacing sheep listeria LI [delta] ilo:: hly with hemolysin, constructing to obtain auxotrophic sheep listeria LI [delta] ilo:: hly [delta] dal [delta] dat; the fusion antigen is constructed by alternately arranging amino terminal and carboxyl terminal structural domains of four types of HPV6 / 11 / 16 / 18 E6 and E7 proteins and retaining an overlapping region of 16 amino acids at a connecting site; inserting the fusion antigen into a non-resistance plasmid pCW631 which carries a dal gene and replaces an Amp gene with an asd gene, so as to obtain a non-resistance plasmid pCW636; the resistance-free plasmid pCW636 is electrically transferred into the auxotroph sheep listeria monocytogenes LIdeltailo:: hly deltadal deltadat, and the sheep listeria monocytogenes cervical cancer vaccine is obtained. The cervical cancer vaccine provided by the invention can express the E6E7 protein in a multivalent manner, so that multiple protection on cervical cancer is realized.

The invention belongs to the technical field of cellulose hydrolysis, and discloses a construction method of a cellulose enzymolysis micro-homogeneous system and a recycling method of cellulase. In a water-phase system, a micro-homogeneous system is formed between the modified cellulase and cellulose, and the cellulose is subjected to enzymolysis; the preparation method comprises the following steps: introducing a polyethylene glycol derivative polyethylene glycol dibenzaldehyde FA-PEG-FA into an amino terminal of cellulase to obtain the modified cellulase, which is marked as FA-Cell. According to the method, a polyethylene glycol derivative is introduced to the amino terminal of the cellulase, so that the cellulase and cellulose form a micro-homogeneous reaction system under an aqueous medium, the enzymatic hydrolysis is prompted to be transited from a heterogeneous phase to a homogeneous phase, and the efficient recovery of the cellulase is realized by utilizing the pH sensitive characteristic of a dynamic Schiff base bond.

To provide an adhesive resin composition which has high flexibility and excellent impact resistance and followability, is particularly suitable for the fields of a housing material, a marine vessel and the like, and is usable without a solvent.SOLUTION: An adhesive resin composition contains a curing agent containing a polyurethane urea resin (D) which is a reaction product of polyol (A), polyisocyanate (B) and polyamine (C) (excluding polyether polyamine (E)) and has an amino group at a terminal, and polyether polyamine (E), and a main agent containing a liquid epoxy resin (F), and satisfies all the following (i) to (iii). (i) In 100 mass% of the total of an organic component having a primary amino group, an organic component having a secondary amino group, and an organic component having an epoxy group, which are contained in the adhesive resin composition, 15 to 40 mass% of the polyurethane urea resin (D) is contained. (ii) The polyamine (C) has a number average molecular weight of less than 300. (iii) The total of the molar numbers of the primary amino group and the secondary amino group in the polyurethane urea resin (D) is 3 to 40 mol%, with respect to 100 mol% of the total of the molar numbers of the primary amino group and the secondary amino group in the polyether polyamine (E).SELECTED DRAWING: None

The invention belongs to the technical field of polypeptide derivative synthesis, and particularly relates to a long-acting tocopherol succinate modified tripeptide-1 derivative as well as a preparation method and application thereof. In the long-acting tocopherol succinate modified tripeptide-1 derivative provided by the invention, tocopherol is connected with an amino terminal of tripeptide-1 through amidation by taking succinic acid as a connecting arm, and a carboxyl terminal of the tripeptide-1 is free carboxyl, ester group or acylamino. The long-acting tocopherol succinate modified tripeptide-1 derivative provided by the invention has good solubility in both a water phase and an oil phase, is beneficial to formula design in an application process, has good antioxidant activity and skin cell injury protection activity, further reduces expression of matrix metalloproteinase and inflammatory factors increased due to ROS (Reactive Oxygen Species), and can be used for preparing the long-acting tocopherol succinate modified tripeptide-1 derivative. The collagen essence has excellent cell matrix stability, can promote collagen expression for a long time, and has good anti-oxidation and wrinkle fading effects when being used for cosmetics or skin care products.

The invention provides a whey protein isolate source antioxidant polypeptide, the amino acid sequence of the whey protein isolate source antioxidant polypeptide is amino terminal-LVYPFPGPIP-carboxyl terminal, and the whey protein isolate source antioxidant polypeptide can be developed into an antioxidant.

The present disclosure relates to bispecific binding proteins comprising, from the amino terminal to the carboxy terminal, (a) a first moiety, which is an anti-BAFF antibody or antigen binding fragment thereof, and (b) a second moiety, which is an anti-MASP2scFv or truncated TACI polypeptide. Furthermore, the invention relates to nucleic acid molecules encoding such bispecific binding proteins, as well as vectors and host cells comprising such nucleic acid molecules. The invention further relates to a method for producing said bispecific binding proteins and to the use of said bispecific binding proteins in the treatment of autoimmune diseases.

This disclosure generally relates to fusion proteins comprising TAL Arrays targeting a repetitive element and a transposase domain comprising amino terminal deletions, as well as dual cysteine rich domains (CRD), for targeting site-specific transposition into ribosomal DNA (rDNA) repeats or LINE1 repetitive elements, polynucleotides and vectors encoding the fusion proteins, and methods of use therefor.